Talfirastide

Talfirastide (TXA127) is a synthetic copy of angiotensin-(1-7), a seven-amino-acid peptide that activates the Mas receptor - the counter-regulatory arm of the renin-angiotensin system that pushes back against the inflammation and vasoconstriction driven by angiotensin II [1]. The drug was developed by Tarix Pharmaceuticals (later renamed Constant Therapeutics) and has been tested across hypertension, insulin resistance in obesity, hematopoietic recovery after chemotherapy, oral mucositis, and most recently severe COVID-19. The headline trial - a 343-patient RCT in hospitalized COVID-19 patients published in JAMA in 2023 - missed its primary endpoint of oxygen-support-free days through day 28 and stopped early for futility, deflating the most visible commercial bet on this asset [1]. The Vanderbilt-sponsored metabolic study (NCT02646475) tested whether activating Mas improves insulin sensitivity in obese adults using hyperinsulinemic-euglycemic clamp endpoints [2]. Maximum phase reached is 2. No drug targeting Mas has ever been approved for any indication, so talfirastide remains a first-in-class story with one large negative readout already on the books and no publicly verifiable active sponsor activity since 2023.

Novel synthetic peptide, never approved anywhere. Highest phase reached is 2 per ChEMBL records. The node previously listed Phase 1 because it was tied to the specific Vanderbilt trial NCT02646475, but the broader program reached Phase 2 in the COVID-19 RCT (Self et al., JAMA 2023) and in earlier Phase 2 work on hematopoietic recovery and oral mucositis under Tarix [1]. No FDA breakthrough, orphan, or fast-track designations are publicly verifiable for talfirastide. The COVID-19 program ran through standard regulatory channels and did not produce a positive readout that would have triggered accelerated pathways. Original sponsor was Tarix Pharmaceuticals (founded ~2007), rebranded as Tarix Orphan and then Constant Therapeutics, based in Cambridge MA. The audit flag on this node is correct: Vanderbilt University is the academic trial site, not the commercial developer. Concrete anchor on staleness: Constant Therapeutics' last publicly verifiable trial sponsorship traces to the ACTIV-4 HT COVID-19 platform RCT (enrollment completed 2022, published JAMA April 2023) [1]. No new ClinicalTrials.gov registrations under Tarix Pharmaceuticals or Constant Therapeutics as sponsor have appeared since 2023 that I can confirm. No press releases, financing announcements, or pipeline updates from the company are publicly verifiable as of June 2026. The company's last verifiable funding event predates the COVID-19 readout and current operational status could not be confirmed from public sources. Treat the asset as operationally dormant until a sponsor surfaces with a new trial registration.

The renin-angiotensin system has two arms. The well-known arm runs ACE to angiotensin II to the AT1 receptor, which raises blood pressure, drives inflammation, and promotes tissue scarring. Every ACE inhibitor (lisinopril, ramipril) and ARB (losartan, valsartan) ever sold works by blocking this arm. The second arm runs ACE2 to angiotensin-(1-7) to the Mas receptor and does roughly the opposite: vasodilates, dampens inflammation, and reduces fibrosis [3]. Talfirastide is a stable synthetic copy of the natural angiotensin-(1-7) peptide. The thesis is straightforward: instead of blocking the bad arm with an ARB, you turn up the good arm directly by feeding the Mas receptor its agonist. Animal data going back two decades support this. Mas-knockout mice show worse cardiac fibrosis, glucose intolerance, and lung injury, and Mas activation rescues those phenotypes [4]. The genetic and preclinical case for Mas as a target is real. The clinical case is thin. No drug targeting Mas has ever been approved for any indication. The natural peptide has a half-life measured in minutes once it hits the bloodstream, which is why TXA127 is dosed parenterally and why oral formulations using hydroxypropyl-β-cyclodextrin (HPβCD) carriers are still being explored [5]. The biggest unknown for patients is whether activating this arm pharmacologically produces a clinical effect large enough to matter - the COVID-19 RCT result suggests, in that population at least, it did not [1]. The non-peptide Mas agonist AVE0991 (a Sanofi tool compound) and other peptide agonists like CGEN-856S have been used extensively in preclinical work, but no small-molecule oral Mas agonist is known to have advanced to clinical Phase 2 as of 2026.

The node references NCT02646475, a Vanderbilt-run mechanistic study testing whether subcutaneous TXA127 improves insulin sensitivity in obese, insulin-resistant adults. Small sample, single-site, mechanistic endpoints (glucose disposal during a hyperinsulinemic-euglycemic clamp, not HbA1c). This is academic pharmacology work, not a registration trial [2]. The commercially meaningful trial was the COVID-19 RCT published by Self et al. in JAMA 2023, part of the ACTIV-4 Host Tissue platform: 343 hospitalized COVID-19 patients randomized to synthetic angiotensin-(1-7), an AT1R biased ligand (TRV027), or placebo. Primary endpoint was oxygen-support-free days through day 28. Synthetic Ang(1-7) showed no benefit over placebo across primary and key secondary endpoints, and enrollment was stopped early for futility [1]. An earlier 30-patient pilot in severe COVID-19 (Wagener et al., Crit Care 2022) had hinted at directional benefit but was underpowered for hard endpoints [6]. The COVID-19 rationale, while ultimately not borne out, was mechanistically plausible at the time and deserves to be stated rather than dismissed. SARS-CoV-2 enters cells by binding ACE2, the enzyme that produces angiotensin-(1-7) from angiotensin II. Viral binding internalizes and downregulates surface ACE2, which in theory reduces local Ang(1-7) production and tilts the renin-angiotensin axis toward the damaging AT1 arm - driving the pulmonary inflammation, microvascular dysfunction, and ARDS-like pathology seen in severe COVID-19. Replacing Ang(1-7) directly was the logical pharmacologic response. The thinness of the rationale was in the unknowns: the in-vivo magnitude of ACE2 downregulation, whether it actually limited Ang(1-7) availability at relevant tissue sites, and whether timing in hospitalized late-stage patients could plausibly reverse established lung injury. The negative readout suggests one or more of those links did not hold up clinically. The pre-2020 Tarix Phase 2 work in chemotherapy-induced thrombocytopenia (hematopoietic recovery) and chemotherapy-induced oral mucositis completed in the early 2010s. Verified primary-endpoint results for those trials are not available and the company never published high-profile registrational follow-ups; the absence of a Phase 3 program in either indication is the clearest available signal that endpoints did not justify further investment. The cardio-metabolic indications, where the Mas axis has the strongest preclinical support, have not had a large well-powered Phase 2 yet. No active Phase 3 trials for talfirastide are registered.

Our model gives this drug a 4% chance of eventually being approved. It starts from the historical approval rate for Phase 2 drugs in this area, which is about 27%, then adjusts based on ten facts about the trial and sponsor. The estimate falls well below that starting point because the sponsor has a thin or weak approval record, earlier-phase results were limited, enrollment is smaller than typical for this phase, and the trial uses a randomized design. The remaining facts were close to average for this stage and did not move the number much.

Efficacy risk dominates. The JAMA 2023 RCT showed no benefit in hospitalized COVID-19 patients on hard clinical endpoints, and while that was a tough population, it raises the question of whether pharmacologic Mas activation produces effect sizes that translate to bedside outcomes [1]. The pre-2020 Phase 2 work in hematopoietic recovery and oral mucositis under Tarix never converted to a registrational program, which is its own bearish signal even without published primary-endpoint failure data. Safety has not been the limiter. The peptide is well tolerated across studies with no on-target cardiovascular signals - appropriate for a drug that vasodilates and dampens inflammation rather than the opposite [6]. The Mas-knockout phenotype implies that turning the receptor up should be physiologically safe. The question is potency, not toxicity. Execution risk is structural. The peptide's minute-scale half-life forces parenteral dosing or specialized oral formulations, limiting both trial design flexibility and commercial appeal versus oral small molecules. Patient selection is unsolved: there is no validated biomarker for identifying patients with low endogenous Ang(1-7) tone who would be most likely to respond. The COVID-19 indication burned the program's most visible shot on goal without yielding a biomarker hypothesis to carry forward. IP / exclusivity risk is material. Composition-of-matter patents on synthetic angiotensin-(1-7) and the original TXA127 formulations trace back to filings under Tarix Pharmaceuticals in the mid-2000s; on standard 20-year patent terms the parent composition claims are likely expired or near expiry. Any commercially viable revival program would need to rely on formulation patents (e.g., HPβCD oral formulation), method-of-use claims for specific indications, or regulatory exclusivity (e.g., orphan designation). Specific patent numbers or expiry dates could not be confirmed from public sources. Commercial risk is acute. Even if a follow-on Phase 2 succeeds in diabetic nephropathy or HFpEF, talfirastide would compete against entrenched cheap generics (ARBs, ACE inhibitors), SGLT2 inhibitors, and GLP-1 agonists. Peptide pricing demands a clean differentiation story (a defined responder population or add-on benefit on top of guideline-directed therapy) that has not yet been established.

Mostly noise at the moment. The asset has a clearly negative Phase 2 in COVID-19, no announced active Phase 3, no publicly verifiable sponsor activity since 2023, no validated biomarker for patient selection, and a parent-compound IP position that is likely expired or near expiry. The underlying biology - angiotensin-(1-7) acting through Mas as a counter-regulatory arm of the renin-angiotensin system - remains genuinely interesting, but interesting biology without an engaged developer is a watch item, not a trade. Specific data points that would convert this to active interest: (1) Constant Therapeutics or a new acquirer announcing a focused Phase 2 in HFpEF, diabetic kidney disease, or hepatic fibrosis with biomarker enrichment and a clear primary endpoint; (2) a well-powered investigator-initiated trial showing a clean effect on a hard endpoint (eGFR slope, NT-proBNP, liver stiffness); (3) any pharma advancing a small-molecule oral Mas agonist (currently no clinical-stage candidates beyond peptide TXA127 and preclinical tools like AVE0991 that I can confirm) into Phase 2, which would validate the target commercially and bring renewed attention to TXA127's first-mover position; (4) credible oral bioavailability and pharmacodynamic data from the HPβCD-Ang(1-7) formulation work [5]; (5) any public funding/financing announcement from Constant Therapeutics or successor entity confirming the program is still alive. Check back in 6-12 months. Two questions to track: is anyone running a meaningful trial of talfirastide in a cardio-metabolic indication, and is anyone publishing oral-bioavailable small-molecule Mas agonists from medicinal chemistry programs? Until one of those moves, treat this as a parked asset with real underlying biology, expiring composition IP, and no near-term catalyst.

Audit corrections are sound: gene_symbol now reflects the drug name (Talfirastide) rather than the endogenous peptide, protein_name no longer leaks the trial title, and the Mas receptor target with UniProt P04201 is populated correctly. Two outstanding flags are worth acting on. (1) Companies list is academic-only - Vanderbilt is the trial site for NCT02646475, not the commercial developer. Add Constant Therapeutics (formerly Tarix Pharmaceuticals) as the true developer, with a note that the sponsor's current operational status is unverifiable as of June 2026. (2) Region (pharma.cardiology) is defensible given the angiotensin axis and hypertension indication, but the Vanderbilt trial is metabolic and several investigated indications are endocrine; pharma.cardiology is the best single bucket but pharma.diabetes is a reasonable secondary tag if the schema supports it. Phase=2 is correct as the program maximum. Status is reasonable as 'phase2' but the active development status is genuinely uncertain - the most recent published large trial readout was 2023 and there is no public Phase 3. If the schema supports a 'dormant' or 'last_readout_date' field, this asset is a candidate (last_readout_date = 2023-04, sponsor_last_active = 2023). No Phase 3 listed is accurate.